MedTrace Logo

BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome

NCT04684654 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2023-08-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, drug levels, and drug effects of BMS-986325 in healthy participants and participants with primary Sjögren's syndrome. The results will guide the future clinical development with BMS-986325.

Conditions

  • Healthy Participants
  • Primary Sjögren's Syndrome

Interventions

BIOLOGICAL

BMS-986325

Specified dose on specified days

OTHER

Placebo for BMS-986325

Specified dose on specified days

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-16
Primary Completion
2023-07-25
Completion
2023-07-25
FDA Drug
Yes

Countries

  • United States
  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04684654 on ClinicalTrials.gov